|Bid||32.45 x 800|
|Ask||54.40 x 900|
|Day's Range||42.90 - 45.60|
|52 Week Range||36.20 - 82.49|
|Beta (5Y Monthly)||1.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||85.81|
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
One of the biotech industry’s up-and-coming gene therapy companies is further delaying its plans for a U.S. drug launch, citing disagreements with FDA officials and the COVID-19 pandemic.
LEXINGTON, Mass. and AMSTERDAM, March 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced it has achieved the targeted dosing of patients in the HOPE-B pivotal trial of etranacogene dezaparvovec (AMT-061), an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. The targeted number of patients to be dosed per the clinical trial protocol was 50. “I am very proud of the entire uniQure team, our investigators, study coordinators and the hemophilia patient communities who helped make this major milestone possible,” stated Matt Kapusta, chief executive officer of uniQure.
With new financing in its pocket, a Flagship Pioneering-backed cell therapy startup is ready to begin its first in-human tests of a rare disease treatment.
LEXINGTON, Mass. and AMSTERDAM, March 03, 2020 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe.
uniQure (QURE) delivered earnings and revenue surprises of -24.36% and 49.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, March 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, and Gen-X, a spin-off company from the Netherlands Cancer Institute, today announced that they have signed an exclusive research collaboration and license agreement with Gen-X, with an option for uniQure to acquire Gen-X, to identify novel synthetic promoters for use in gene therapy products. Gen-X performs functional annotation of the non-coding genome using its proprietary Survey of Regulatory Elements (SuRE) technology.
~ Patient Dosing Nearly Completed in Phase III HOPE-B Trial of Etranacogene Dezaparvovecin Hemophilia B ~ ~ First Patient Procedure in Phase I/II Clinical Trial of AMT-130 in.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presentation of multiple new preclinical data on AMT-130, its investigational AAV gene therapy for the treatment of Huntington’s disease (HD), at the 15th Annual CHDI Huntington’s disease Therapeutics Conference in Palm Springs, California. “Our data presentations at CHDI illustrate the increasing potential of AMT-130 to target the highly toxic exon 1 protein fragment, achieve broad vector biodistribution across several animal species and show meaningful activity using the presence of extracellular vesicles as a potential biomarker,” stated Sander van Deventer, M.D., Ph.D., executive vice president, research & product development of uniQure.
If you own shares in uniQure N.V. (NASDAQ:QURE) then it's worth thinking about how it contributes to the volatility of...
UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2020 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 31, 2020 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
One of Cambridge’s emerging gene therapy startups has raised $110 million to support the company as it heads toward in-human trials. Generation Bio closed the Series C round this week, bringing in new investors T. Rowe Price, Farallon and Wellington Management, as well as previous backers Atlas Venture, Fidelity and others. The Series C round brings the total money raised by Generation Bio to more than $235 million.
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Massachusetts life science companies were involved in $34 billion worth of mergers and acquisitions this year. Experts say next year will be even busier.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 19, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced two publications of preclinical data from its gene therapy candidate AMT-130 in Huntington’s disease, in the journals Nucleic Acids Research and Molecular Therapy – Methods & Clinical Development. The first publication in Nucleic Acids Research examines the tolerability and efficacy of non-selective huntingtin protein (HTT) lowering using an AAV5 encoded micro-RNA targeting human HTT (AAV5-miHTT) in the humanized Hu128/21 mouse model of Huntington’s disease.
Two of the industry’s leading gene-editing experts have unveiled their next venture: a gene-silencing startup called Triplet Therapeutics.
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
~ Sustained FIX Activity at Therapeutic Levels1 Up to 50% of Normal at One Year After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ ~ Zero Bleeds and No.
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics